gabapentin has been researched along with Chronic Disease in 145 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough." | 9.30 | Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019) |
| " Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions." | 9.27 | GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 9.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "The aim of this study was to compare the efficacy and side effects of gabapentin, amitriptyline, and their combination in women with chronic pelvic pain." | 9.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 9.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 9.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 8.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "In the present work, we investigated the antinociceptive effect of gabapentin in a chronic myositis model and its interference in spinal glial cells." | 7.85 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 7.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 7.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "Chronic pruritus is a distressing symptom that is often refractory to treatment." | 6.53 | Gabapentin and pregabalin for the treatment of chronic pruritus. ( Kwatra, SG; Matsuda, KM; Schonfeld, AR; Sharma, D, 2016) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 5.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "To compare the efficacy of gabapentin and baclofen in patients with suspected refractory gastro-oesophageal reflux-induced chronic cough." | 5.30 | Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. ( Chen, Q; Ding, H; Dong, R; Lv, H; Pan, J; Qiu, Z; Shi, C; Xu, X; Yu, L; Yu, Y; Zhang, M, 2019) |
| " Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions." | 5.27 | GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018) |
| "Compared with gabapentin, duloxetine has no obvious advantage in the treatment of diabetic peripheral neuralgia, but it has less side effects and significantly higher safety." | 5.22 | Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis. ( Cui, J; Jiang, L; Xiong, Y, 2022) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The purpose of this study was to evaluate the analgesic effects of perioperative gabapentin on postoperative acute and chronic pain after coronary artery bypass graft (CABG) surgery with median sternotomy and internal mammary artery harvesting." | 5.15 | The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. ( Onan, B; Selcuk, I; Sen, H; Turan, A; Ucak, A; Yilmaz, AT, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 5.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| " Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos." | 5.11 | Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005) |
| "The aim of this study was to compare the efficacy and side effects of gabapentin, amitriptyline, and their combination in women with chronic pelvic pain." | 5.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 5.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 5.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| ", opioids and gabapentin) are centrally-acting drugs primarily used for pain and neuropathic conditions; they were not designed for cough and have limitations with respect to efficacy and safety." | 5.05 | Pharmacotherapeutic Options for Chronic Refractory Cough. ( Chung, KF; Song, WJ, 2020) |
| " Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (FM)." | 4.91 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 4.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Objective To evaluate the short- and long-term effects of tricyclic antidepressants (TCAs) and gabapentin in the treatment of unexplained chronic cough (UCC)." | 3.88 | Short- and Long-term Effects of Neuromodulators for Unexplained Chronic Cough. ( Adessa, M; Benninger, MS; Bowen, AJ; Bryson, PC; Contrera, K; Kaltenbach, J; Milstein, CF; Nowacki, AS; Taliercio, R; Trask, D, 2018) |
| "In the present work, we investigated the antinociceptive effect of gabapentin in a chronic myositis model and its interference in spinal glial cells." | 3.85 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 3.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| "A pharmacokinetic-pharmacodynamic (PK/PD) model relating pain relief to gabapentin plasma concentrations was derived from a phase 3 study." | 3.72 | The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. ( Cook, JA; Ewy, WE; Lockwood, PA; Mandema, JW, 2003) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 3.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| " The outcome measures included scores: (1) for the improvement in the degree of sleep interference score; (2) for the improvement in sleep quality; (3) for the rate of poor sleep quality; (4) for the rate awakenings of >5 per night; and (5) for the incidence of adverse reactions." | 3.01 | Efficacy and Safety of Gabapentin in Improving Sleep Quality of Patients with Sensory Nervous System Diseases: A Meta-Analysis. ( Jiang, W; Li, W; Ma, M; Shen, Y, 2023) |
| " Higher oral dosing and longer treatment regimens of gabapentin may be indicated for the treatment of chronic musculoskeletal pain in horses." | 2.94 | Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness. ( Bauck, AG; Gilliam, LL; Kembel, SL; Schoonover, MJ; Taylor, JD; Young, JM, 2020) |
| "Assessment of postoperative pain at 1, 3 and 6 months was carried out with an 11-point numerical rating scale; 0 indicating 'no pain' and 10 indicating 'worst pain imaginable'." | 2.74 | The effects of gabapentin on acute and chronic pain after inguinal herniorrhaphy. ( Dağli, G; Inangil, G; Ozkan, S; Sen, H; Senol, MG; Sizlan, A; Sücüllü, I; Yanarateş, O, 2009) |
| "Chronic neuropathic pain occurs in 10-15% of patients with neuroborreliosis and is difficult to treat." | 2.71 | Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. ( Hofmann, H; Ring, J; Weissenbacher, S, 2005) |
| "Cough is a common respiratory symptom that is considered to be chronic when it lasts more than eight weeks." | 2.66 | Management of chronic refractory cough in adults. ( Beghè, B; Fabbri, LM; Papi, A; Spanevello, A; Visca, D, 2020) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Chronic pruritus is a distressing symptom that is often refractory to treatment." | 2.53 | Gabapentin and pregabalin for the treatment of chronic pruritus. ( Kwatra, SG; Matsuda, KM; Schonfeld, AR; Sharma, D, 2016) |
| "Chronic refractory cough has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition." | 2.52 | Management of chronic refractory cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Tinnitus is the perception of sound or noise in the absence of an external or internal acoustic stimulation." | 2.47 | Anticonvulsants for tinnitus. ( Hoekstra, CE; Rovers, MM; Rynja, SP; van Zanten, GA, 2011) |
| "Some mechanisms of the development of neuropathic pain have been proposed; 1) sprouting of A beta fibers to the superficial layer of the dorsal horn, 2) ectopic discharge in the dorsal root ganglion and/or in neuroma at the nerve stump, 3) spinal sensitization." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| "Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations." | 2.44 | Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007) |
| "Gabapentin is a second generation anticonvulsant that is effective in the treatment of chronic neuropathic pain." | 2.44 | Gabapentin: a multimodal perioperative drug? ( Irwin, MG; Kong, VK, 2007) |
| "Migraine and headache studies are excluded in this revision." | 2.43 | Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, H; Moore, A; Wiffen, P, 2005) |
| " Thus, monitoring and dosage adjustment are required, without discontinuation of the drug." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "Patients completed a daily postoperative pain and medication log." | 1.62 | Preoperative Gabapentin Administration and Its Impact on Postoperative Opioid Requirement and Pain in Sinonasal Surgery. ( Beliveau, AM; Gill, AS; Hwang, JC; Steele, TO; Strong, EB; Virani, FR; Wilson, MD, 2021) |
| "Gabapentin (GBP) is an established drug that has been used in the management of symptoms of neuropathy but it is associated with unwanted side effects such as sedation and motor incoordination." | 1.62 | A novel gabapentin analogue assuages neuropathic pain response in chronic sciatic nerve constriction model in rats. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| " As only a minority of respondents felt comfortable prescribing these drugs, more education on effective and safe dosing is needed." | 1.51 | Use of Systemic Treatment in Patients with Chronic Pruritus: A Survey of Dermatologists in the Netherlands. ( Kamsteeg, M; Kouwenhoven, TA; van de Kerkhof, PCM, 2019) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Gabapentin was used by 45% as first-, second-, or third-line treatment." | 1.46 | International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. ( Bieber, BA; Ecder, T; Graham-Brown, M; Hasegawa, T; Kleophas, W; Larkina, M; Pisoni, RL; Rayner, HC; Robinson, BM; Tentori, F; van der Veer, SN; Wang, M, 2017) |
| "Gabapentin failed to suppress the scratching behavior induced by the intradermal injection of compound 48/80 in normal mice." | 1.37 | Gabapentin and pregabalin inhibit the itch-associated response induced by the repeated application of oxazolone in mice. ( Manabe, H; Matsumoto, Y; Miura, H; Tsukumo, Y; Yano, H, 2011) |
| "In rats with four ligatures, prominent mechanical allodynia and thermal hyperalgesia developed; these behavioral signs were not prominent in rats with two ligatures." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "The effect of disc degeneration on behavioral measures of chronic pain has not been evaluated in this model." | 1.37 | Behavioral signs of chronic back pain in the SPARC-null mouse. ( Millecamps, M; Sage, EH; Stone, LS; Tajerian, M, 2011) |
| "Chronic migraine is an important public health problem." | 1.36 | Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. ( D'Amico, D, 2010) |
| "Anxiety and depression are often also present." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "CCI also evoked mechanical allodynia that was fully developed on a week post-operation, but showed no recovery for at least 8 weeks." | 1.35 | Pharmacological characteristics of the hind paw weight bearing difference induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E, 2009) |
| "Pelvic pain was detected 5 days after antigen instillation and was sustained beyond 30 days, indicating the development of chronic pain." | 1.35 | Experimental autoimmune prostatitis induces chronic pelvic pain. ( Rudick, CN; Schaeffer, AJ; Thumbikat, P, 2008) |
| "The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS)." | 1.33 | Motor cortex stimulation for central pain following a traumatic brain injury. ( Choi, ES; Hong, JT; Lee, SW; Son, BC; Sung, JH, 2006) |
| "Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive." | 1.33 | Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2005) |
| "Six children with cerebral palsy are presented who developed neuropathic pain following multilevel orthopedic surgery." | 1.33 | Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. ( Lauder, GR; White, MC, 2005) |
| "Gabapentin has been shown to be useful in treatment of different conditions which may be caused by increased neuronal excitability." | 1.32 | Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin. ( Haller, H; Leblhuber, F; Schmidhammer, R; Trenkler, J, 2003) |
| "SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60." | 1.31 | Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001) |
| "Gabapentin was effective in approximately 50% of pretreated patients with intractable pain." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 1.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (6.21) | 18.2507 |
| 2000's | 75 (51.72) | 29.6817 |
| 2010's | 50 (34.48) | 24.3611 |
| 2020's | 11 (7.59) | 2.80 |
| Authors | Studies |
|---|---|
| Hong-Ju, Y | 1 |
| He, L | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Jiang, L | 1 |
| Xiong, Y | 1 |
| Cui, J | 1 |
| Guilleminault, L | 1 |
| Demoulin-Alexikova, S | 1 |
| de Gabory, L | 1 |
| Bruley des Varannes, S | 1 |
| Brouquières, D | 1 |
| Balaguer, M | 1 |
| Chapron, A | 1 |
| Grassin Delyle, S | 1 |
| Poussel, M | 1 |
| Guibert, N | 1 |
| Reychler, G | 1 |
| Trzepizur, W | 1 |
| Woisard, V | 1 |
| Crestani, S | 1 |
| Shen, Y | 2 |
| Li, W | 1 |
| Ma, M | 1 |
| Jiang, W | 2 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 2 |
| Li, Y | 4 |
| Li, L | 3 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Li, J | 5 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 4 |
| Hu, X | 1 |
| Li, Z | 2 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 1 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Zhang, X | 2 |
| Yang, X | 2 |
| Zhang, J | 2 |
| Wang, H | 1 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 1 |
| Song, H | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 2 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 2 |
| Geng, Y | 1 |
| Zhang, Y | 3 |
| Wang, X | 2 |
| Liu, J | 2 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Yu, ZY | 1 |
| Wu, L | 2 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Li, S | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 1 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Chen, X | 2 |
| Mo, J | 1 |
| Zhang, S | 2 |
| Li, X | 1 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 1 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 1 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Zhang, M | 2 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 1 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 1 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 1 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Young, JM | 1 |
| Schoonover, MJ | 1 |
| Kembel, SL | 1 |
| Taylor, JD | 1 |
| Bauck, AG | 1 |
| Gilliam, LL | 1 |
| Lee, MY | 1 |
| Taliercio, RM | 1 |
| Adessa, M | 2 |
| Milstein, C | 1 |
| Bryson, PC | 2 |
| Song, WJ | 1 |
| Chung, KF | 1 |
| Gill, AS | 1 |
| Virani, FR | 1 |
| Hwang, JC | 1 |
| Wilson, MD | 1 |
| Beliveau, AM | 1 |
| Strong, EB | 1 |
| Steele, TO | 1 |
| Visca, D | 1 |
| Beghè, B | 1 |
| Fabbri, LM | 1 |
| Papi, A | 1 |
| Spanevello, A | 1 |
| Russell, M | 1 |
| Zare, M | 1 |
| Ahmad, N | 1 |
| Subhan, F | 1 |
| Islam, NU | 1 |
| Shahid, M | 1 |
| Ullah, N | 1 |
| Ullah, R | 1 |
| Akbar, S | 1 |
| Amin, MU | 1 |
| Khurram, M | 1 |
| Ullah, I | 1 |
| Sewell, RDE | 1 |
| Lee, HG | 1 |
| Grossman, SK | 1 |
| Valdes-Rodriguez, R | 1 |
| Berenato, F | 1 |
| Korbutov, J | 1 |
| Chan, YH | 1 |
| Lavery, MJ | 1 |
| Yosipovitch, G | 2 |
| Wiffen, PJ | 4 |
| Derry, S | 3 |
| Bell, RF | 1 |
| Rice, AS | 2 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 4 |
| Espinosa-Juárez, JV | 1 |
| Jaramillo-Morales, OA | 1 |
| López-Muñoz, FJ | 1 |
| Kohse, EK | 1 |
| Hollmann, MW | 1 |
| Bardenheuer, HJ | 1 |
| Kessler, J | 1 |
| Giliberto, JP | 2 |
| Dibildox, D | 1 |
| Merati, A | 1 |
| Rayner, HC | 1 |
| Larkina, M | 1 |
| Graham-Brown, M | 1 |
| van der Veer, SN | 1 |
| Ecder, T | 1 |
| Hasegawa, T | 1 |
| Kleophas, W | 1 |
| Bieber, BA | 1 |
| Tentori, F | 1 |
| Robinson, BM | 1 |
| Pisoni, RL | 1 |
| Miao, J | 1 |
| Aboagye, DE | 1 |
| Chulpayev, B | 1 |
| Liu, L | 1 |
| Ishkanian, G | 1 |
| Kolanuvada, B | 1 |
| Alaie, D | 1 |
| Petrillo, RL | 1 |
| Vincent, K | 1 |
| Baranowski, A | 1 |
| Bhattacharya, S | 1 |
| Birch, J | 1 |
| Cheong, Y | 1 |
| Cregg, R | 1 |
| Daniels, J | 1 |
| Hewitt, CA | 1 |
| Macfarlane, GJ | 1 |
| Middleton, L | 1 |
| Szubert, W | 1 |
| Tracey, I | 1 |
| Williams, ACC | 1 |
| Horne, AW | 1 |
| Bowen, AJ | 1 |
| Nowacki, AS | 1 |
| Contrera, K | 1 |
| Trask, D | 1 |
| Kaltenbach, J | 1 |
| Milstein, CF | 1 |
| Benninger, MS | 1 |
| Taliercio, R | 1 |
| Pereira, MP | 1 |
| Basta, S | 1 |
| Moore, J | 1 |
| Ständer, S | 1 |
| Reszke, R | 1 |
| Szepietowski, JC | 1 |
| Kouwenhoven, TA | 1 |
| van de Kerkhof, PCM | 1 |
| Kamsteeg, M | 1 |
| Dong, R | 1 |
| Xu, X | 1 |
| Yu, L | 1 |
| Ding, H | 1 |
| Pan, J | 1 |
| Yu, Y | 1 |
| Shi, C | 1 |
| Chen, Q | 1 |
| Lv, H | 1 |
| Qiu, Z | 1 |
| Bernhard, JD | 1 |
| Fostini, AC | 1 |
| Girolomoni, G | 1 |
| Tessari, G | 1 |
| Toelle, T | 1 |
| Parker, L | 1 |
| Huelin, R | 1 |
| Khankhel, Z | 1 |
| Wasiak, R | 1 |
| Mould, J | 1 |
| Wu, CH | 1 |
| Gunasekara, K | 1 |
| Hull, JH | 1 |
| Bikov, A | 1 |
| Morris, AJ | 1 |
| Usmani, OS | 1 |
| Ryan, NM | 2 |
| Inkpen, H | 1 |
| Gibson, PG | 3 |
| Vertigan, AE | 2 |
| Nakazato-Imasato, E | 1 |
| Kurebayashi, Y | 1 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Nascimento-Alves, P | 1 |
| Fernandes-Silva, H | 1 |
| Aragão-Homem, C | 1 |
| Geraldes, R | 1 |
| Fonseca, AC | 1 |
| Robertson, KL | 1 |
| Marshman, LA | 1 |
| Matsuda, KM | 1 |
| Sharma, D | 1 |
| Schonfeld, AR | 1 |
| Kwatra, SG | 1 |
| Ward, RE | 1 |
| Veerula, VL | 1 |
| Ezra, N | 1 |
| Travers, JB | 1 |
| Mousdicas, N | 1 |
| Cohen, SM | 2 |
| Misono, S | 2 |
| Rosa, AS | 1 |
| Freitas, MF | 1 |
| Rocha, IR | 1 |
| Chacur, M | 1 |
| Forde, G | 2 |
| Stanos, S | 1 |
| Levy, BS | 1 |
| Apgar, BS | 1 |
| Yamamoto, T | 1 |
| Fürst, Z | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 2 |
| Nicoletti, F | 1 |
| Sen, H | 3 |
| Sizlan, A | 2 |
| Yanarateş, O | 2 |
| Senol, MG | 1 |
| Inangil, G | 1 |
| Sücüllü, I | 1 |
| Ozkan, S | 2 |
| Dağli, G | 2 |
| Gatti, A | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| Clarke, H | 1 |
| Pereira, S | 1 |
| Kennedy, D | 1 |
| Andrion, J | 1 |
| Mitsakakis, N | 1 |
| Gollish, J | 1 |
| Katz, J | 1 |
| Kay, J | 1 |
| Jensen, TS | 1 |
| Finnerup, NB | 1 |
| Emirkadi, H | 1 |
| Turan, A | 2 |
| Yildirim, K | 1 |
| Deniz, O | 1 |
| Gureser, G | 1 |
| Karatay, S | 1 |
| Ugur, M | 1 |
| Erdal, A | 1 |
| Senel, K | 1 |
| Morris-Stiff, G | 1 |
| Lewis, MH | 1 |
| Strauss, AC | 1 |
| Dimitrakov, JD | 1 |
| Greene, SM | 1 |
| Simpson, CB | 1 |
| Flatters, SJ | 1 |
| D'Amico, D | 1 |
| Amr, YM | 1 |
| Yousef, AA | 1 |
| Bar Ad, V | 1 |
| Heidelbaugh, JJ | 1 |
| Llanes, M | 1 |
| Weadock, WJ | 1 |
| Millecamps, M | 1 |
| Tajerian, M | 1 |
| Sage, EH | 1 |
| Stone, LS | 1 |
| Tsukumo, Y | 1 |
| Matsumoto, Y | 1 |
| Miura, H | 1 |
| Yano, H | 1 |
| Manabe, H | 1 |
| Ucak, A | 1 |
| Onan, B | 1 |
| Selcuk, I | 1 |
| Yilmaz, AT | 1 |
| McQuay, HJ | 2 |
| Hey, M | 1 |
| Wilson, I | 1 |
| Johnson, MI | 1 |
| Obata, H | 2 |
| Ogino, Y | 1 |
| Hoekstra, CE | 1 |
| Rynja, SP | 1 |
| van Zanten, GA | 1 |
| Rovers, MM | 1 |
| Lantos, PM | 1 |
| Gunduz, O | 1 |
| Oltulu, C | 1 |
| Guven, R | 1 |
| Buldum, D | 1 |
| Ulugol, A | 1 |
| Lua, J | 1 |
| Bellamy, CO | 1 |
| Whitworth, C | 1 |
| Dhaun, N | 1 |
| Birring, SS | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Surges, R | 1 |
| Feuerstein, TJ | 1 |
| Fassoulaki, A | 2 |
| Patris, K | 1 |
| Sarantopoulos, C | 2 |
| Hogan, Q | 1 |
| Bortalanza, LB | 1 |
| Ferreira, J | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 1 |
| Haller, H | 1 |
| Leblhuber, F | 1 |
| Trenkler, J | 1 |
| Schmidhammer, R | 1 |
| Oefelein, MG | 1 |
| Bayazit, Y | 1 |
| Lockwood, PA | 1 |
| Cook, JA | 1 |
| Ewy, WE | 1 |
| Mandema, JW | 1 |
| Spira, PJ | 1 |
| Beran, RG | 1 |
| von Orelli, F | 1 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Nicholson, BD | 1 |
| Lotery, HE | 1 |
| McClure, N | 1 |
| Galask, RP | 1 |
| Stahl, SM | 1 |
| Baldassano, CF | 1 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Urban, MO | 1 |
| Ren, K | 1 |
| Park, KT | 1 |
| Campbell, B | 1 |
| Anker, N | 1 |
| Stearns, B | 1 |
| Aiyar, J | 1 |
| Belley, M | 1 |
| Cohen, C | 1 |
| Bristow, L | 1 |
| Lauder, GR | 1 |
| White, MC | 1 |
| Heartsill, LG | 1 |
| Brown, TM | 1 |
| Wiffen, P | 1 |
| Collins, S | 1 |
| McQuay, H | 1 |
| Carroll, D | 1 |
| Jadad, A | 1 |
| Moore, A | 1 |
| Edwards, JE | 1 |
| Weissenbacher, S | 1 |
| Ring, J | 1 |
| Hofmann, H | 1 |
| Coderre, TJ | 1 |
| Kumar, N | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Triga, A | 1 |
| Melemeni, A | 1 |
| Sator-Katzenschlager, SM | 1 |
| Scharbert, G | 1 |
| Kress, HG | 2 |
| Frickey, N | 1 |
| Ellend, A | 1 |
| Gleiss, A | 1 |
| Kozek-Langenecker, SA | 1 |
| Persaud, R | 1 |
| Frosh, A | 1 |
| Son, BC | 1 |
| Lee, SW | 1 |
| Choi, ES | 1 |
| Sung, JH | 1 |
| Hong, JT | 1 |
| Mintz, S | 2 |
| Lee, JK | 2 |
| Kehlet, H | 1 |
| Cohen, SP | 1 |
| Sireci, A | 1 |
| Wu, CL | 1 |
| Larkin, TM | 1 |
| Williams, KA | 1 |
| Hurley, RW | 1 |
| Bichuetti, DB | 1 |
| Yamaoka, WY | 1 |
| Bastos, JR | 1 |
| Carvalho, Dde S | 1 |
| Kimos, P | 1 |
| Biggs, C | 1 |
| Mah, J | 1 |
| Heo, G | 1 |
| Rashiq, S | 1 |
| Thie, NM | 1 |
| Major, PW | 1 |
| Bergasa, NV | 1 |
| McGee, M | 1 |
| Ginsburg, IH | 1 |
| Engler, D | 1 |
| Pawlik, MT | 1 |
| Ittner, KP | 1 |
| Vadalouca, A | 1 |
| Siafaka, I | 1 |
| Argyra, E | 1 |
| Vrachnou, E | 1 |
| Moka, E | 1 |
| Hauer, JM | 1 |
| Wical, BS | 1 |
| Charnas, L | 1 |
| Manenti, L | 1 |
| Vaglio, A | 1 |
| Jatzko, A | 1 |
| Stegmeier-Petroianu, A | 3 |
| Petroianu, GA | 1 |
| Solak, O | 2 |
| Metin, M | 1 |
| Esme, H | 1 |
| Yaman, M | 1 |
| Pekcolaklar, A | 1 |
| Gurses, A | 1 |
| Kavuncu, V | 1 |
| Sinclair, AM | 1 |
| Miller, B | 1 |
| Lee, LK | 1 |
| Petroianu, G | 3 |
| Kong, VK | 1 |
| Irwin, MG | 1 |
| Hayashida, K | 1 |
| Schuchmann, JA | 1 |
| Browne, BA | 1 |
| Ketz, AK | 1 |
| Rudick, CN | 1 |
| Schaeffer, AJ | 1 |
| Thumbikat, P | 1 |
| Benbouzid, M | 1 |
| Choucair-Jaafar, N | 1 |
| Yalcin, I | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Bras, M | 1 |
| Haslam, C | 1 |
| Nurmikko, T | 1 |
| Hunter, JC | 1 |
| Gogas, KR | 1 |
| Hedley, LR | 1 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| García-Albea, E | 1 |
| Hein, G | 2 |
| Petroianu, A | 1 |
| Bergler, W | 2 |
| Rüfer, R | 2 |
| Langan, Y | 1 |
| Duncan, JS | 1 |
| Sander, JW | 3 |
| Hansen, HC | 1 |
| Wong, IC | 2 |
| Chadwick, DW | 1 |
| Fenwick, PB | 1 |
| Mawer, GE | 1 |
| Ben-David, B | 1 |
| Friedman, M | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Nasuelli, D | 1 |
| Cazzato, G | 1 |
| Kapadia, NP | 1 |
| Harden, N | 1 |
| Fragoso, YD | 1 |
| Carrazana, EJ | 1 |
| Lhatoo, SD | 1 |
| Polizzi, G | 1 |
| Hulsebosch, CE | 2 |
| Xu, GY | 1 |
| Perez-Polo, JR | 1 |
| Westlund, KN | 1 |
| Taylor, CP | 1 |
| McAdoo, DJ | 1 |
| Mills, CD | 1 |
| Grady, JJ | 1 |
| Gustorff, B | 1 |
| Nahlik, G | 1 |
| Spacek, A | 1 |
| To, TP | 1 |
| Lim, TC | 1 |
| Hill, ST | 1 |
| Frauman, AG | 1 |
| Cooper, N | 1 |
| Kirsa, SW | 1 |
| Brown, DJ | 1 |
| Bruins Slot, LA | 1 |
| Tarayre, JP | 1 |
| Koek, W | 1 |
| Ribet, JP | 1 |
| Colpaert, FC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Effectiveness of Sertraline in Alleviating Uremic Pruritis in Hemodialysis Patients[NCT05341843] | Phase 2 | 60 participants (Actual) | Interventional | 2022-05-01 | Completed | ||
| Phenomics and Genomics of Clinically Relevant Chronic Postsurgical Pain: A Multicenter Prospective Study[NCT04798573] | 10,000 participants (Anticipated) | Observational | 2012-08-03 | Active, not recruiting | |||
| Pre-Emptive Analgesia in Ano-Rectal Surgery[NCT02402543] | 90 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| The Effect of Intravenous Infusions of Lidocaine and Magnesium Versus Lidocaine and Ketamine Versus Lidocaine Alone on Recovery Profile and Postoperative Pain After Elective Gynecological Surgery[NCT04622904] | 90 participants (Anticipated) | Interventional | 2020-11-14 | Recruiting | |||
| Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia[NCT03066739] | Phase 2 | 105 participants (Anticipated) | Interventional | 2023-02-25 | Recruiting | ||
| Diagnostic Challenges in IC (and Male CPPS)[NCT00672087] | 1,000 participants (Anticipated) | Observational | 2003-09-30 | Completed | |||
| The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain[NCT01619852] | 148 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology[NCT01403168] | 28 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Recruitment difficulties) | |||
| Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy[NCT02104466] | 40 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study[NCT03494426] | 70 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Study of Gabapentin for the Pruritus of Cholestasis[NCT00058890] | Phase 3 | 15 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children[NCT01675960] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to unable to enroll) | ||
| The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair[NCT02419443] | Phase 4 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236] | 62 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574] | Phase 3 | 41 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The participants development of chronic persistent pain 3 months after surgery as determined by character severity (yes/no). (NCT01619852)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Group L | 2 |
| .9% Normal Saline Placebo | 6 |
The amount of opioid analgesics consumed was converted to an equivalent dose of intravenous morphine. (NCT01619852)
Timeframe: 24 hours
| Intervention | equivalent dose of intravenous morphine (Median) |
|---|---|
| Group L | 34 |
| .9% Normal Saline Placebo | 39 |
Postoperative pain within the first 24 hours. Area under the numeric rating scale for pain versus time curve during the first 24 hours after surgery (score * hr). Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve during the first 24 hours ( score * hr). The pain scores were collected upon arrival to recovery area, 30 minutes, 1 hour and every 6 hours up to 24 hours following the procedure. Minimum score is 60, Maximum score is 170. A higher value indicates more pain. (NCT01619852)
Timeframe: 24 hours
| Intervention | score on a scale (Median) |
|---|---|
| Group L | 116 |
| .9% Normal Saline Placebo | 119 |
Quality of recovery (QoR-40 instrument) is a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Score range: 40 to 200. A score of 40 demonstrates poor recovery and a maximum score of 200 represents good recovery. The higher the score the better recovery after surgery. (NCT01619852)
Timeframe: 24 hours post operative
| Intervention | units on a scale (Median) |
|---|---|
| Lidocaine (Group L) | 158 |
| .9% Normal Saline Placebo | 169 |
The development of chronic pain 3 months after surgery determined by the Leads Assessment of Neuropathic Symptoms and Signs (LANSS) scale, a valid 7-item tool for identifying patients whose pain is dominated by neuropathic mechanisms. Each item is a binary response (yes or no) to the presence of symptoms (5 items) or clinical signs (2 items), range 0-24 points. A score ≥ 12, neuropathic mechanisms are likely to be contributing to the patient's pain. A score < 12 is unlikely to be contributing. McGill questionnaire (Sensory domain) - 11 descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe. The higher the score, greater the pain (range 0-33). McGill questionnaire (Motivational-affective) 4 affect descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe.The higher the score the greater the pain (range 0-12) Brief pain inventory - pain severity (0, no pain, 10 excruciating pain); Greater the score; greater the pain (range 0-10). (NCT01619852)
Timeframe: 3 months
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| S-LANNS | McGill Questionaire-Sensory Discrimation | McGill Questionaire-Motivational-affective | Brief Pain Inventory | |
| .9% Normal Saline Placebo | 3 | 3 | 0 | 1 |
| Group L | 3 | 4 | 0 | 1 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
(NCT00886236)
Timeframe: 48 hours
| Intervention | % oxygen saturation (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 93 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 94 |
| 3 Preoperative and Postoperative Placebo Liquid | 95 |
The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours
| Intervention | ml (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 11.035 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 8.7 |
| 3 Preoperative and Postoperative Placebo Liquid | 12.4 |
(NCT00886236)
Timeframe: 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 12 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 11 |
| 3 Preoperative and Postoperative Placebo Liquid | 12 |
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
46 reviews available for gabapentin and Chronic Disease
| Article | Year |
|---|---|
Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis.
Topics: Analgesics; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Duloxetine Hydrochlor | 2022 |
Efficacy and Safety of Gabapentin in Improving Sleep Quality of Patients with Sensory Nervous System Diseases: A Meta-Analysis.
Topics: Chronic Disease; Gabapentin; Humans; Multicenter Studies as Topic; Sleep; Sleep Initiation and Maint | 2023 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Pharmacotherapeutic Options for Chronic Refractory Cough.
Topics: Analgesics, Opioid; Antitussive Agents; Chronic Disease; Cough; Gabapentin; Humans; Pyrimidines; Qua | 2020 |
Management of chronic refractory cough in adults.
Topics: Adult; Asthma; Chronic Disease; Cough; Gabapentin; Humans; Quality of Life | 2020 |
How to assess and relieve that perplexing rashless itch.
Topics: Antipruritics; Chronic Disease; Diagnosis, Differential; Evidence-Based Medicine; Gabapentin; Humans | 2020 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Chronic Hiccups: An Underestimated Problem.
Topics: Amines; Anesthesiology; Baclofen; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Am | 2017 |
End-Stage Renal Disease Chronic Itch and Its Management.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antipruritics; Chronic Disease; Cyclohexanecarboxylic A | 2018 |
Clinical practice. Chronic pruritus.
Topics: Amines; Antidepressive Agents, Tricyclic; Behavior Therapy; Chronic Disease; Cyclohexanecarboxylic A | 2013 |
Prurigo nodularis: an update on etiopathogenesis and therapy.
Topics: Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Dermatologic Agents; Epidermis; Female; Gabape | 2013 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia; | 2014 |
A systematic review of pharmacoeconomic studies for pregabalin.
Topics: Amines; Analgesics; Anticonvulsants; Chronic Disease; Cost-Benefit Analysis; Cyclohexanecarboxylic A | 2015 |
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Gabapentin in chronic cough.
Topics: Amines; Animals; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2015 |
Management of chronic refractory cough.
Topics: Adaptation, Psychological; Amines; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
Gabapentin and pregabalin for the treatment of chronic pruritus.
Topics: Amines; Anti-Anxiety Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma | 2016 |
Are neuromodulating medications effective for the treatment of chronic neurogenic cough?
Topics: Amines; Amitriptyline; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2017 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
The complex nature of chronic pelvic pain.
Topics: Adult; Amines; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, | 2007 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
New treatments for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Amines; Chronic Disease; Cognitive Behavioral Therapy; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2010 |
Evidence for sensory neuropathy and pharmacologic management.
Topics: Adrenergic Uptake Inhibitors; Amines; Amitriptyline; Anticonvulsants; Chronic Disease; Cough; Cycloh | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
An algorithm for the treatment of chronic testicular pain.
Topics: Algorithms; Amines; Analgesics; Anesthetics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 2010 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2011 |
[Molecular mechanisms and clinical pharmacology of chronic pain].
Topics: Amines; Animals; Anterior Horn Cells; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanecarb | 2010 |
Anticonvulsants for tinnitus.
Topics: Administration, Oral; Amines; Anticonvulsants; Carbamazepine; Chronic Disease; Cyclohexanecarboxylic | 2011 |
Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review.
Topics: Amines; Amitriptyline; Baclofen; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2013 |
Mode of action of gabapentin in chronic neuropathic pain syndromes. A short review about its cellular mechanisms in nociceptive neurotransmission.
Topics: Acetates; Amines; Animals; Biogenic Monoamines; Calcium Channels; Chronic Disease; Cyclohexanecarbox | 2002 |
[Nonorganic pain -- only psychogenic?].
Topics: Acetates; Adult; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Back Pain; Chronic Dise | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2005 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
Bilateral SUNCT syndrome associated to chronic maxillary sinus disease.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2006 |
Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2006 |
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis; | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
[Alpha2-adrenergic receptors in the dorsal horn of the spinal cord--their function and the descending inhibitory systems].
Topics: Acetylcholine; Adrenergic alpha-2 Receptor Agonists; Amines; Analgesics; Animals; Brain-Derived Neur | 2007 |
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis | 2007 |
Pain management in the traumatic amputee.
Topics: Acute Disease; Afghanistan; Amines; Amputation, Traumatic; Analgesia; Analgesics; Benchmarking; Caus | 2008 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
Treatment of chronic pain with antiepileptic drugs: a new era.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapen | 1999 |
25 trials available for gabapentin and Chronic Disease
| Article | Year |
|---|---|
Efficacy of orally administered gabapentin in horses with chronic thoracic limb lameness.
Topics: 4-Butyrolactone; Analgesics; Animals; Chronic Disease; Cross-Over Studies; Drug Therapy, Combination | 2020 |
Gabapentin not effective for chronic pelvic pain in women.
Topics: Adolescent; Adult; Analgesics; Chronic Disease; Double-Blind Method; Female; Gabapentin; Humans; Mid | 2021 |
GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol.
Topics: Adolescent; Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; D | 2018 |
Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough.
Topics: Adult; Analgesics; Baclofen; Chronic Disease; Cough; Dose-Response Relationship, Drug; Female; Follo | 2019 |
Gabapentin Superadded to a Pre-Existent Regime Containing Amytriptyline for Chronic Sciatica.
Topics: Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Chronic Disease; Cohort Studies; | 2016 |
The effects of gabapentin on acute and chronic pain after inguinal herniorrhaphy.
Topics: Adult; Amines; Analgesics; Anesthesia, Spinal; Chronic Disease; Cyclohexanecarboxylic Acids; Double- | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality.
Topics: Administration, Oral; Adult; Amines; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain.
Topics: Acute Disease; Adult; Amines; Analgesics; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic A | 2010 |
The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Chronic Pain; Coronary | 2011 |
Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Central Nervous System; Chronic Disease; Cough; Cyclohex | 2012 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics; Anticonvulsants; Ataxia; Chronic Disease; Cro | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; | 2005 |
Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.
Topics: Acute Disease; Adult; Amines; Analgesia; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cycl | 2005 |
Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study.
Topics: Adult; Amines; Amitriptyline; Austria; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Combinatio | 2005 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Amines; Analgesics; Cholestasis; Chronic Disease; Cyclohexanecarboxylic Acids; Double-Blind M | 2006 |
Effectiveness of gabapentin in the treatment of chronic post-thoracotomy pain.
Topics: Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy.
Topics: Acetates; Adult; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Cohort Studies; Cyclohex | 1999 |
Treatment of chronic: new perspectives.
Topics: Acetates; Aged; Amines; Cerebral Infarction; Chronic Disease; Cyclohexanecarboxylic Acids; Excitator | 1999 |
Low doses of gabapentin may be helpful in the management of chronic daily headache.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic | 2000 |
74 other studies available for gabapentin and Chronic Disease
| Article | Year |
|---|---|
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
[Guidelines for the management of chronic cough in adults].
Topics: Adult; Amitriptyline; Chronic Disease; Cough; Gabapentin; Humans; Quality of Life | 2023 |
A cough that won't go away: Evaluation and treatment in 2 patients.
Topics: Aged; Analgesics, Opioid; Botulinum Toxins; Chronic Disease; Cognitive Behavioral Therapy; Cough; Di | 2020 |
Preoperative Gabapentin Administration and Its Impact on Postoperative Opioid Requirement and Pain in Sinonasal Surgery.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Chronic Disease; Female; Gabapentin; Humans; Male; Midd | 2021 |
A novel gabapentin analogue assuages neuropathic pain response in chronic sciatic nerve constriction model in rats.
Topics: Analgesics; Animals; Behavior, Animal; Chronic Disease; Constriction; Disease Models, Animal; Excita | 2021 |
Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability.
Topics: Aged; Amines; Amitriptyline; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Therapy, | 2017 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough.
Topics: Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Female; Gabap | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
Topics: Amines; Analgesics; Autoantibodies; Biomarkers; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2018 |
Short- and Long-term Effects of Neuromodulators for Unexplained Chronic Cough.
Topics: Adult; Aged; Amitriptyline; Chronic Disease; Cohort Studies; Cough; Dose-Response Relationship, Drug | 2018 |
Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Gabapentin; Histamine Antagonists; Huma | 2018 |
Use of Systemic Treatment in Patients with Chronic Pruritus: A Survey of Dermatologists in the Netherlands.
Topics: Adult; Antidepressive Agents; Antipruritics; Chronic Disease; Dermatologists; Drug Prescriptions; Fe | 2019 |
Gabapentin as a potential treatment for cough syncope.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Chronic progressive polyarthritis in a domestic shorthair cat.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats; | 2015 |
Pharmacological characteristics of the hind paw weight bearing difference induced by chronic constriction injury of the sciatic nerve in rats.
Topics: Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Disease Models, Animal; G | 2009 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
IV and V cranial nerves dysfunction as initial manifestations of superficial siderosis of the central nervous system.
Topics: Aged; Amines; Angiography, Digital Subtraction; Atrophy; Central Nervous System Diseases; Cerebellum | 2016 |
Multilevel symmetric neuropathic pruritus (MSNP) presenting as recalcitrant "generalized" pruritus.
Topics: Age Distribution; Aged; Amines; Chronic Disease; Cohort Studies; Cyclohexanecarboxylic Acids; Diseas | 2016 |
Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis.
Topics: Amines; Animals; Astrocytes; Behavior, Animal; Cell Count; Chronic Disease; Cyclohexanecarboxylic Ac | 2017 |
Challenges of fragmented care in long-term management of pelvic pain.
Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr | 2007 |
Fibromyalgia: poorly understood; treatments are disappointing.
Topics: Acetaminophen; Acupuncture Therapy; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2009 |
Neuropathic pain treatment: a further step forward.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2010 |
Effect of analgesic standards on persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR).
Topics: Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Dermatologic Surgical Pro | 2010 |
Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.
Topics: Amines; Analgesics; Chronic Disease; Clonidine; Cyclohexanecarboxylic Acids; Diagnosis, Differential | 2010 |
Behavioral signs of chronic back pain in the SPARC-null mouse.
Topics: Age Factors; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Chronic Diseas | 2011 |
Gabapentin and pregabalin inhibit the itch-associated response induced by the repeated application of oxazolone in mice.
Topics: Amines; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2011 |
Stellate ganglion blockade (SGB) for refractory index finger pain - a case report.
Topics: Abdominal Pain; Accidental Falls; Acetaminophen; Adult; Amines; Autonomic Nerve Block; Chronic Disea | 2011 |
Chronic Lyme disease: the controversies and the science.
Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise | 2011 |
Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
Topics: Amines; Amitriptyline; Analgesics; Animals; Benzoxazines; Chronic Disease; Constriction; Cyclohexane | 2011 |
Quiz Page October 2011: An under-recognized cause of CKD.
Topics: Acidosis; Amines; Anorexia Nervosa; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Creati | 2011 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Arm; Carbamazepine; Central Cord Syndrome; Cervical Ver | 2003 |
Chronic pain syndrome after laparoscopic radical nephrectomy.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Carcinoma, Renal Cell; Carcinoma, Transition | 2003 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Clinical Trials, Phase II as Topic; Computer Simulati | 2003 |
Vulvodynia.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Chroni | 2004 |
Gabapentin (Neurontin) for chronic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Costs; Drug Interac | 2004 |
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; G | 2004 |
Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Benzylamines; Chronic Disease; Cyclohexanecarb | 2005 |
Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cerebral Palsy; Chi | 2005 |
Use of gabapentin for rest pain in chronic critical limb ischemia.
Topics: Amines; Analgesics; Bed Rest; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2005 |
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Amines; Analgesics; Animals; Aspartic Acid; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory | 2005 |
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologists.
Topics: Amines; Anticonvulsants; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids | 2006 |
Motor cortex stimulation for central pain following a traumatic brain injury.
Topics: Accidental Falls; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Aphasia, Broca; Brain Inju | 2006 |
Gabapentin in the treatment of intractable idiopathic chronic cough: case reports.
Topics: Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; | 2006 |
Perioperative analgesia to prevent chronic postmastectomy pain.
Topics: Amines; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2006 |
Pulsed radiofrequency of the dorsal root ganglia is superior to pharmacotherapy or pulsed radiofrequency of the intercostal nerves in the treatment of chronic postsurgical thoracic pain.
Topics: Adult; Amines; Analgesics; Anticonvulsants; Carbamazepine; Catheter Ablation; Chronic Disease; Cyclo | 2006 |
[Post-operative pain therapy of a chronic pain patient].
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Co | 2006 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Amines; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Diagnosis, Diff | 2006 |
Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment.
Topics: Adolescent; Adult; Amines; Analgesics; Child; Child, Preschool; Chronic Disease; Cyclohexanecarboxyl | 2007 |
Gabapentin use in chronic uraemic itch is in line with emerging pathogenetic hypothesis.
Topics: Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; P | 2007 |
Alpha-2-delta ligands for singultus (hiccup) treatment: three case reports.
Topics: Aged; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; Gabap | 2007 |
Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cycloh | 2007 |
[The 10-minute-consultation: chronic singultus].
Topics: Aged; Amines; Anti-Ulcer Agents; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Diag | 2007 |
Experimental autoimmune prostatitis induces chronic pelvic pain.
Topics: Amines; Analgesics; Anesthetics, Local; Animals; Autoimmune Diseases; Chronic Disease; Cyclohexaneca | 2008 |
Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain; Chronic Di | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
[Prophylactic treatment with gabapentin in chronic daily headache resistant to other drugs].
Topics: Acetates; Adult; Aged; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Resist | 1998 |
[ETICS Study: Empirical therapy of idiopathic chronic singultus].
Topics: Acetates; Aged; Aged, 80 and over; Amines; Baclofen; Chronic Disease; Cisapride; Cyclohexanecarboxyl | 1998 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
Gabapentin therapy for vulvodynia.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic | 1999 |
Gabapentin "add-on therapy" for idiopathic chronic hiccup (ICH).
Topics: Acetates; Aged; Amines; Baclofen; Chronic Disease; Cisapride; Cyclohexanecarboxylic Acids; Drug Admi | 2000 |
Gabapentin for chronic pain in spinal cord injury: a case report.
Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2000 |
Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Topics: Acetates; Adolescent; Adult; Age of Onset; Aged; Amines; Anticonvulsants; Chronic Disease; Cyclohexa | 2000 |
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar | 2000 |
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh | 2001 |
[Gabapentin in the treatment of chronic intractable pain].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non | 2002 |
Gabapentin for neuropathic pain following spinal cord injury.
Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci | 2002 |
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag | 2002 |